ArticleExperimental and therapeutic medicine2021
Metformin attenuates H
Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Effects of cisplatin and tamoxifen chemotherapy on peri-implant bone remodeling around titanium implants in ovariectomized rats: An in vivo study.Journal of periodontology · 2026Article
- Single-pore silica nanotherapeutic platform with pH-Responsive NO release for osteoporosis repair.Materials today. Bio · 2026Article
- Dose-Dependent Impact of Metformin on Osteoblast-Specific Biomarkers in Cultured Rat Primary Osteoblasts.Physiological research · 2026Article
- Sirtuins in Women's Health.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Addressing osteoblast senescence: Molecular pathways and the frontier of anti-ageing treatments.Clinical and translational medicine · 2025Review
- Beyond Bone Loss: A Biology Perspective on Osteoporosis Pathogenesis, Multi-Omics Approaches, and Interconnected Mechanisms.Biomedicines · 2025Review
- Metformin and bone metabolism: unraveling their direct and indirect effects.Therapeutic advances in endocrinology and metabolism · 2025Review
- Regulation of aging-related chronic diseases by dietary polyphenols: An updated overview.Current research in food science · 2025Review
- Mitochondria: a key regulator of programmed cell death in OP.Frontiers in endocrinology · 2025Review
- Metformin improves HPRT1-targeted purine metabolism and repairs NR4A1-mediated autophagic flux by modulating FoxO1 nucleocytoplasmic shuttling to treat postmenopausal osteoporosis.Cell death & disease · 2024Article
- Epimedium-Curculigo herb pair enhances bone repair with infected bone defects and regulates osteoblasts through LncRNA MALAT1/miR-34a-5p/SMAD2 axis.Journal of cellular and molecular medicine · 2024Article
- Advances in SIRT3 involvement in regulating autophagy-related mechanisms.Cell division · 2024Review
- Metformin treatment reduces the incidence of osteoporosis: a two-sample Mendelian randomized study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- SIRT3: A Potential Target of Different Types of Osteoporosis.Cell biochemistry and biophysics · 2024Review
- Metformin prevents mandibular bone loss in a mouse model of accelerated aging by correcting dysregulated AMPK-mTOR signaling and osteoclast differentiation.Journal of orthopaedic translation · 2024Article
- Application of extracellular vesicles in diabetic osteoporosis.Frontiers in endocrinology · 2024Review
- The Differential Effect of Metformin on Osteocytes, Osteoblasts, and Osteoclasts.Current osteoporosis reports · 2023Review
- Metformin reverses oxidative stress‑induced mitochondrial dysfunction in pre‑osteoblasts via the EGFR/GSK‑3β/calcium pathway.International journal of molecular medicine · 2023Article
- Mitochondrial quality control and its role in osteoporosis.Frontiers in endocrinology · 2023Review
- Role of SIRT3 in bone homeostasis and its application in preventing and treating bone diseases.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a common metabolic disease that has a high incidence in postmenopausal women. Studies have indicated that oxidative damage plays an important role in the development of postmenopausal osteoporosis. Metformin has been showed to have the ability to relieve excessive oxidation. The aim of the present was to determine the therapeutic effect and potential mechanism of metformin in postmenopausal osteoporosis. Oxidative damage was stimulated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.